beta-agonists

The drugs, known as long-acting beta-agonists, or LABAs, are used by about six million asthma patients whose symptoms aren't well-controlled by other drugs including inhaled corticosteroids, which are the backbone of asthma treatment and are designed to reduce airway inflammation.

FDA to Implement New 'Safety Controls' for Some Asthma Drugs Jennifer Corbett Dooren 2010

The drugs, known as long-acting beta-agonists, or LABAs, are used by about six million asthma patients whose symptoms aren't well-controlled by other drugs including inhaled corticosteroids, which are the backbone of asthma treatment and are designed to reduce airway inflammation.

FDA to Implement New 'Safety Controls' for Some Asthma Drugs Jennifer Corbett Dooren 2010

The drugs, known as long-acting beta-agonists, or LABAs, are designed to prevent the tightening of muscles around the airway.

Corporate Watch 2010

Patients who get their allergy treatment from primary-care providers are more likely to overuse beta-agonists than patients who see allergists — largely, says Tringale, because allergists are "better able pinpoint the best treatment for their patients the first time."

The City of Too Much Medicine Makes News Again 2009

The drugs, known as long-acting beta-agonists, or LABAs, are used by about six million asthma patients whose symptoms aren't well-controlled by other drugs, including inhaled corticosteroids, which are the backbone of asthma treatment and are designed to reduce airway inflammation.

Panel Weighs Asthma Drugs 2008

The drugs fall into a class of medications known as long-acting beta-agonists, or LABAs, and have been the subject of an ongoing FDA safety review.

FDA: Long-Acting Asthma Drugs Increase Asthma Risks 2008

The drugs, known as long-acting beta-agonists, or LABAs, are used by about six million asthma patients whose symptoms aren't well-controlled by other drugs including inhaled corticosteroids, which are the backbone of asthma treatment, and are designed to reduce airway inflammation.

FDA Panel Says Some Asthma Drugs Too Risky 2008

The drugs, known as long-acting beta-agonists, or LABAs, are used by about six million asthma patients whose symptoms aren't well-controlled by other drugs, including inhaled corticosteroids, which are the backbone of asthma treatment and are designed to reduce airway inflammation.

FDA Panel Says Some Asthma Drugs Too Risky 2008

Advair, by GlaxoSmithKline PLC, and Symbicort, by AstraZeneca, fall into a class of drugs known as long-acting beta-agonists, or LABAs.

FDA Panel Is Split on Risks of Some Asthma Drugs 2008

Doctor, first let's start with what are the beta-agonists?

CNN Transcript Jun 26, 2004 2004